The effects of hepatitis C virus non-structural protein 3 on cell growth mediated by extracellular signal-related kinase cascades in human hepatocytes in vitro by unknown
Abstract. Hepatitis C virus (HCV) infection has become a
severe health problem worldwide. The viral proteins are
believed to be among the most important factors that contribute
to HCV mediated pathogenesis. Accumulated evidence
demonstrating that HCV non-structural protein 3 (NS3)
possesses oncogenic potential, and is involved in the regulation
of cell proliferation has been documented. In this study, we
emphasized the effect of HCV NS3 protein on cell proliferation
in the immortally normal hepatocyte QSG7701 cells. The cell
line transfected with plasmid expressing NS3 protein showed
enhanced cell growth, extracellular signal-related kinase (ERK)
activation, DNA binding activities of transcription factors of
activator protein 1 (AP-1) and NF-κB, and cyclin D1 over-
expression, but without activation of Jun amino-terminal kinase
or p38. Pre-treatment of NS3 protein expressing cells with ERK
inhibitor, PD98059, blocked the activation of AP-1 and NF-κB,
and inhibited cyclin D1 expression and cell proliferation. The
results suggest that NS3-mediated cell growth occurs through
activation of ERK/AP-1 and NF-κB/cyclin D1 cascades. 
Introduction
Hepatitis C is an infectious disease caused by the hepatitis C
virus (HCV). The disease affects ~200 million people world-
wide (1). HCV infections often progress to persistent infection
and advance to severe liver injury such as chronic hepatitis C,
liver cirrhosis and primary hepatocyte carcinoma (HCC) when
the immune system of acute HCV-infected patients fails to
clear the virus or responds poorly to antiviral therapy (2).
HCV is an enveloped, single-stranded positive-sense RNA
virus that belongs to the family Flaviviridae. The 9.6-kb viral
genome encodes a precursor polyprotein of ~3,010 amino
acids, which is cleaved by both the cellular and viral proteases
into at least 4 structural proteins (core, E1, E2 and p7) and
6 non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A,
and NS5B). 
Non-structural protein 3 (NS3) possesses serine protease
activity, which is important for viral protein processing (3),
and nucleotide triphosphatase-RNA helicase activity, which is
essential for virus replication (4-7). Besides its pivotal role in
viral protein processing and virus replication, the HCV NS3
protein was reported to be involved in malignant transformation
of NIH3T3 cells (8). Our previous study also showed the
oncogenic potential of HCV NS3 N terminal protein (9). 
In our previous study, we found that HCV NS3 N terminal
protein can activate the mitogen-activated (MAPK) signaling
pathway extracellular signal-related kinase (ERK) in the
immortally normal hepatocyte QSG7701 cells (10), which
might have been involved in the stimulation of cell growth
(11,12). The disturbance of cell proliferation is closely
associated with carcinogenesis. However, the refined
mechanisms of this regulation remain to be determined. HCV
NS3 N terminal protein and the whole HCV NS3 protein
might possess a different biological manner. To address this
problem, the normal human hepatocyte cell line QSG7701 was
used in this study. The results showed that the cell transfected
the whole HCV NS3 protein, promoting cell growth and
activated ERK/activator protein 1 (AP-1) and NF-κB/cyclin D1
cascades, suggesting that the activation of ERK/AP-1 and
NF-κB/cyclin D1 cascades is essential for the stimulation of
HCV NS3 protein-mediated cell growth in QSG7701 cell line.
Materials and methods
Cell culture. The human hepatocyte cell line QSG7701 was
obtained from the Cell Bank of Type Culture Collection of
Chinese Academy of Sciences, Shanghai Institutes for
Biological Sciences Chinese Academy of Sciences (Shanghai,
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China). Cells were maintained in Dulbecco's modified Eagle's
medium supplemented with 10% fetal calf serum, 100 U/ml
penicillin G, and 100 unit/ml streptomycin, at 37˚C in a
humidified atmosphere of 5% CO2. All cell culture reagents
were from Gibco BRL (Carlsbad, USA). 
Plasmid construction. The HCV cDNA p90HCVconFLlongpU
(13) was kindly provided by Professor Charles M. Rice
(Department of Molecular Microbiology, Washington
University School of Medicine, St. Louis, MO). The non-
expressive plasmid pcDNA3.1(+) was purchased from
Invitrogen (Groningen, The Netherlands). The sense primer
5'-CCC AAG CTT ATG GCG CCC ATC ACG GCG TAC
G-3' contains a start codon (bold) and a HindIII restriction
site (underlined), and the anti-sense primer 5'-CG GGA TCC
TTA CGT GAC GAC CTC CAG GTC GG-3' includes a
stop codon (bold) and a BamHI restriction site (underlined).
These primers were used to amplify the cDNA encoding
regions of HCV NS3 (nt 3340-5244, gene bank #AF009606).
The amplified PCR products were digested by HindIII and
BamHI, and then cloned into pcDNA3.1(+) to generate
pcDNA3.1-NS3 plasmid.
Transfection and selection of cell strains with stable
expression of HCV NS3 protein. DMEM culture medium with
10% fetal calf serum was used to culture QSG7701 cells in
12-well cell culture plates until cells covered 90-95% of the
area. Serum-free DMEM was used for culture overnight. Trans-
fection of cell lines was conducted with a Lipofectamine 2000
liposome transfection kit. According to the directions of the
manufacturer, liposome and plasmid pcDNA3.1-NS3 were
mixed and added to each well. pcDNA3.1 empty vector trans-
fection group and blank control group (only liposome was
added, but no vector DNA) were established. Transfection
was completed after 24 h incubation. Transfected cells were
diluted then selected in medium containing 400 μg/ml G418.
The selection process lasted 31 days to allow colony formation.
Colonies resistant to G418 were isolated with cloning
cylinders and transferred into 24-well dishes. Ten positive
clones were obtained from the plasmid pcDNA3.1-NS3 trans-
fection group (pcDNA3.1-NS3/QSG) and 3 positive clones
were obtained from the pcDNA3.1 empty vector transfection
group (pcDNA3.1/QSG) in QSG7701 cells. The clones
(pcDNA3.1-NS3/QSG) constitutively expressing HCV NS3
protein were validated by reverse transcription polymerase
chain reaction (RT-PCR) and Western blot analysis. QSG7701
cells were also transfected with the non-expression vector
pcDNA3.1(+) as a negative control (pcDNA3.1/QSG).
QSG7701 parental cells were used for the parallel control. 
Experimental groups. Experimental groups include 3 clones
expressing HCV NS3 protein, 1 clone transfected with empty
plasmid pcDNA3.1 and QSG7701 parental cells. Group 1-3,
QSG7701 transfected with plasmid pcDNA3.1-NS3
(QSG7701/NS3-1, 2, 3); 4, QSG7701 transfected with empty
plasmid pcDNA3.1 (QSG7701/pcDNA3.1); 5, QSG7701
parental cells.
RT-PCR. Total cellular RNA was extracted from the cell line
with Trizol reagent (Gibco/BRL) and quantified by UV
absorbance spectroscopy. The reverse transcription reaction
was performed using Takara RNA PCR kit (AMV) Ver. 3.0
(Dalian, China). The newly synthesized cDNA was amplified
by PCR (Takara). Primers involved were, the HCV NS3 gene
(nt4506-5181) primer (forward, 5'-AGA CAT CTC ATC TTC
TGC CAC TCA AA-3; reverse, 5'-GGC GGA TCA AAC
ACT TCC ACA TC-3'); ß-actin primer (forward, 5'-TGA
CGG GGT CAC CCA CAC TGT GCC CAT CTA-3'; reverse,
5'-CTA GAA GCA TTT GCG GTG GAC GAT GGA
GGG-3'). Amplified PCR products were 676 and 661 bp for
HCV NS3 and ß-actin, respectively. Conditions for PCR were
as follows, 95˚C pre-denaturation for 5 min, 95˚C denaturation
for 30 sec, 58˚C annealing for 30 sec, 72˚C extension for 1 min
for 35 cycles followed by 72˚C for 10 min. Aliquots of the
PCR product were electrophoresed on 1.5% agarose gels and
PCR fragments were visualized by UV illumination (UVP
GDS7500 Gel, Upland, CA, USA) stained by ethidium
bromide. The fluorescence intensity of ß-actin fragments
served as the criterion for the HCV NS3 fragments. Densito-
metric analysis was performed using the electrophoresis
image analysis system Smart View 2000 software (Furi,
Shanghai, China).
Western blotting. Western blot analysis was performed with
collected cell lysate as described before (12). Collected
samples were mixed with standard 2x SDS reducing gel-
loading buffer containing 5% ß-mercaptoethanol. Samples
were boiled for 10 min before loaded onto 4-15% SDS-PAGE
gels. After electrophoresis, proteins were transferred onto an
Immobilon-PVDF membrane (Millipore Corp., Bedford, MA)
in 25 mM Tris, 192 mM glycine, and 15% methanol. The
membranes were blocked in 5% non-fat milk (Bio-Rad) in
PBS for 2 h and then probed with antibodies. Antibodies
were used at the following dilutions and obtained from the
indicated sources, anti-HCV NS3 antibody diluted 1:1,000
(Santa Cruz Biotechnology, Santa Cruz, USA); anti-p44/42
MAPK antibody diluted 1:1,000 (#9102, Cell Signaling);
anti-phospho-p44/42 MAPK antibody diluted 1:1,000 (#9101,
Cell Signaling), anti-p38 MAPK antibody diluted 1:1,000
(Sc-7972, Santa Cruz Biotechnologies), and anti-phospho-p38
MAPK diluted 1:1000 (Sc-7973, Santa Cruz Biotechnologies),
anti-SAPK/Jun amino-terminal kinase (JNK) MAPK antibody
diluted 1:1,000 (#9252, Cell Signaling); anti-phospho-SAPK/
JNK MAPK antibody diluted 1:1,000 (#9251, Cell Signaling);
anti-cyclin D1 antibody diluted 1:1,000 (NewMarker). Anti-
ß-actin antibody (1:2,000, Santa Cruz Biotechnology) was
used as a loading control. Horseradish peroxidase conjugated
goat anti-mouse or goat anti-rabbit IgG (H+L) (Bio-Rad
Laboratories, Melville, NY), diluted 1:5,000, was used as a
secondary antibody. Visualization of immunoreactive proteins
was achieved by using the ECL Western blotting detection
reagents (Amersham Corp., Heights, IL) and the membrane
was exposed to a Kodak X-Omat AR film. Molecular weights
of the immunoreactive proteins were determined using two
different sets of protein marker ladders. All experiments were
performed at least three times.
Preparation of nuclear extracts. Cells were harvested at the
indicated time points and nuclear extracts were prepared.
Unless indicated otherwise, all procedures were performed at
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4-8˚C. Briefly, cells were washed with ice-cold PBS buffer
and harvested by the addition of 500 μl of buffer A (10 mM
HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,
1 mM DTT, 0.5 mM PMSF) containing protease inhibitor and
incubated on ice for 10 min. The supernatant was discarded
after centrifugation at 14,000 rpm for 3 min. The pellet was
resuspended in 50 μl of buffer C (20 mM HEPES, pH 7.9,
0.42 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM
PMSF) containing protease inhibitor and incubated for 20 min
at 4˚C and then centrifuged at 14,000 rpm for 3 min. The
supernatant containing nuclear protein was quantified by
BCA protein assay kit and stored at -70˚C. 
Electrophoretic mobility shift assays (EMSA). The operating
procedures of EMSA were according to the LightShift
Chemiluminescent EMSA Kit (#20148, Pierce Biotechno-
logies) protocol. Specific oligonucleotides for binding of
AP-1 (S, 5'-CGC TTG ATG AGT CAG CCG GAA-3'; A, 3'-
GCG AAC TAC TCA GTC GGC CTT-5'), and NF-κB (S, 5'-
AGT TGA GGG GAC TTT CCC AGG C-3'; A, 3'-TCA
ACT CCC CTG AAA GGG TCC G-5') were prepared by
end labeling of the 5'-terminus with Biotin (synthesized by
Bioasia Biotech, Shanghai, China). Three independent
experiments were performed. 
MTT cell proliferation assay. MTT assay was used to analyse
cell proliferation in the sample. Cells were seeded on 96-well
plates at a predetermined optimal cell density to ensure
exponential growth in the duration of the assay. After
incubation for 72 h, 20 μl MTT (5 g/l) was added to each
well and the plate was incubated at 37˚C for 4 h. Then all
culture medium supernatant was removed from wells and
replaced with 100 μl DMSO. Plates were shaken for 15 min.
All formation production induced by MTT was dissolved.
Then, a microplate reader at 492 nm measured the absorbance
in each well. The inhibition of cell growth was calculated by
the equation, growth inhibitory rate = (1 - A492 treated/A492
control) x 100%. The experiment was repeated three times.
Flow cytometry. Cells were seeded at a density of 2x105 cells
per 100-mm culture dish and covered with 5 ml of PrEGM.
After 24 h, the medium was replaced. Flow cytometry was
used to analyse the cell cycle in the sample. Cells were seeded
at a density of 2x105 cells per 100-mm culture dish to ensure
exponential growth for the duration of the assay. After
incubation for 72 h, cells were washed in PBS 3 times and
collected. For flow cytometry analysis, samples were centri-
fuged for 5 min at 200 x g, washed with 5 ml of PBS and then
resuspended in 1 ml of freshly prepared staining solution
[propidium iodide (1 g/l) diluted 1:50 in 0.1% (v/v) Triton X-
100 in PBS containing RNase A (0.2 g/l)]. The analysis was
performed after 30 min of incubation at room temperature.
Cells (10,000) were analyzed for cell cycle distribution using
a Becton Dickinson FACScan flow cytometer equipped with
a 488-nm argon laser and CellQuest software (Becton
Dickinson Immunocytometry Systems, San Jose, CA). Cell
cycle distribution was analyzed by Mod-fit software (Verity
Software House, Topsham, ME). The experiment was
repeated three times.
Statistical analysis. Data were analyzed using the Statistical
Package for Social Science (SPSS Release 11.5; SPSS Inc.,
Chicago, IL, USA). A P-value <0.05 or <0.01 was considered
significant. Results are expressed as the mean ± SD of data
obtained in triplicate. 
Results
HCV NS3 protein expression in QSG7701 cells. HCV NS3
protein expression was detected in QSG7701 cells transfected
with pcDNA3.1-NS3 by RT-PCR and Western blotting. All
of the three positive clones had NS3 protein expression.
However NS3 did not express in pcDNA3.1 transfected and
nontransfected cells (Fig. 1A and B). 
Effects of HCV NS3 protein expression on cell growth. MTT
was repeated 3 times and used to detect the proliferation ability
of QSG7701/NS3-1, 2, 3, QSG7701/pcDNA3.1 and QSG7701
cells, respectively. The results show that proliferation ability of
QSG7701/NS3 was much higher than that of QSG7701/
pcDNA3.1 and nontransfected cells (P<0.05), and no
difference between QSG770/1pcDNA3.1 and QSG7701 cells
(Table I). Cell distribution of the cell cycle was detected by
FCM. Comparing to QSG7701/pcDNA3.1 and QSG7701
cells, the pcDNA3.1-NS3 transfected cells had G1 phase cells
decreased and S phase cells increased (Table II), suggesting
the QSG7701/NS3 cells have advantage in proliferation.
Effect of HCV NS3 protein on phosphorylation of MAPK.
Three groups of MAPK, extracellular signal-related kinase
(ERK)-1/2(P44/42MAPK), JNK, p38 proteins, are closely related
to cell growth in mammalian cells. All of these kinases are
activated by phosphorylation. As shown in Fig. 2, Western
blot analysis demonstrated that HCV NS3 protein does not
alter the expression of JNK, p38, or ERK in QSG7701 cell
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Figure 1. HCV NS3 protein expression in QSG7701 cells. (A) RT-PCR
analysis of the expression of HCV NS3. (B) Western blot analysis of the
expression of HCV NS3. Lane 1, QSG7701/NS3-1; 2, QSG7701/NS3-2; 3,
QSG7701/NS3-3; 4, QSG7701 /pcDNA3.1; 5, QSG7701.
Table I. MTT analysis of cell proliferation.
–––––––––––––––––––––––––––––––––––––––––––––––––
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clones. However the phosphorylation level of ERK was
higher in QSG7701/NS3 cells than in QSG7701/pcDNA3.1
or QSG7701 cells. In contrast there was no change in the
phosphorylation of p38 or JNK. These observations suggest
that HCV NS3 expression has no effect on the basal expression
of MAPK, but mediates the activation of ERK through
inducing phosphorylation, which may be important for the
stimulation of HCV NS3 protein-mediated cell growth.
Detecting the DNA binding activity of AP-1 and NF-κB, and
the expression of cyclin D1 protein. As an important down-
stream effector of ERK, AP-1 regulates directly the expression
of cyclin D1 to affect the progress of the cell cycle. Signal
transcription factor NF-κB is an important modulator of cell
proliferation. To elucidate further the mechanism of the HCV
NS3 protein-mediated cell growth, we detected the DNA
binding activity of AP-1 and NF-κB, and the expression of
cyclin D1 protein. EMSA analysis demonstrated that the
DNA binding activity of AP-1 (Fig. 3A) and NF-κB (Fig. 3B)
in QSG7701/NS3 cells were much higher than that in
QSG7701/pcDNA3.1 and QSG7701 cells. Meanwhile, the
results of Western blotting showed that cyclin D1 (Fig. 3C)
protein expression was also up-regulated in QSG7701/NS3
cells. These results suggest the stimulation of HCV NS3
protein-mediated cell growth may employ the activation of
AP-1 and NF-κB/cyclin D1. 
ERK inhibitor, PD98059, prevents activation of AP-1 and
NF-κB, and the expression of cyclin D1 protein, and cell
growth advantage induced by HCV NS3 protein. ERK
inhibitor, PD98059, specifically inhibits the activation of
ERK (Fig. 4A). In order to determine whether the activation
of ERK by HCV NS3 protein, is directly associated with the
induced cell growth of QSG7701, we used PD98059 to block
ERK activity and investigated the effect on HCV NS3 induced
cell growth. In the inhibition experiments, one of the three
QSG7701/NS3 cell clones was taken randomly as an
experimental cell clone, and cells were pre-treated with
PD98059 at 0, 30, 50 and 100 μM for 48 h before the
evaluation of ERK activation. Results of EMSA revealed that
the PD98059 inhibits HCV NS3-induced activation of AP-1
(Fig. 4B) and NF-κB (Fig. 4C), and Western blotting showed
that HCV NS3-induced expression of cyclin D1 was decreased
(Fig. 4D). MTT (Fig. 4E) and FCM (Table III) analysis
illustrated that PD98059 can down-regulate HCV NS3-induced
proliferation. These results suggest that the activation of AP-1
and NF-κB/cyclin D1, which were induced to express HCV
NS3 protein, occurs as a direct consequence of HCV-induced
activation of ERK. In addition, the ability of PD98059 to
inhibit the HCV NS3 protein-mediated cell growth suggests
that the activation of the ERK signaling pathway is essential
for stimulation of HCV NS3 protein-mediated proliferative
activity. 
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Table II. FCM analysis of cell cycle.
–––––––––––––––––––––––––––––––––––––––––––––––––
Groups G1 (%) S (%)
–––––––––––––––––––––––––––––––––––––––––––––––––
1, QSG7701/NS3-1 67.0 24.8
2, QSG7701/NS3-2 70.5 21.4
3, QSG7701/NS3-3 67.1 21.8
4, QSG7701/pcDNA3.1 77.0 13.9




Figure 2. Effects of HCV NS3 protein on the expression and phosphorylation
of JNK, p38, and ERK. Western-blotting analysis of the expression and
phosphorylation of ERK (A), JNK (B) and p38 (C) in QSG7701/NS3-1, 2, 3,
QSG7701/pcDNA3.1 and QSG7701 cells. The same blots were re-probed
with an anti-actin antibody to compare loading and transfer. These results are
representative of three independent experiments. Lane 1, QSG7701/NS3-1;
2, QSG7701/NS3-2; 3, QSG7701/NS3-3; 4, QSG7701 /pcDNA3.1; 5,
QSG7701.
Figure 3. Effects of HCV NS3 protein on the DNA binding activity of AP-1
and NF-κB, and the expression of cyclin D1 protein. Nuclear extracts were
prepared and equal amounts of nuclear proteins (6 μg) were analyzed for the
activity of AP-1 (A) and NF-κB (B). Western blot analysis of the expression
of cyclin D1 (C) in QSG7701/NS3-1, 2, 3, QSG7701/pcDNA3.1 and
QSG7701 cells. The same blots were re-probed with an anti-actin antibody
to compare loading and transfer. These results are representative of three
independent experiments. Lane 1, QSG7701/NS3-1; 2, QSG7701/NS3-2; 3,
QSG7701/NS3-3; 4, QSG7701/pcDNA3.1; 5, QSG7701.
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Discussion
HCV infection has become a severe health problem worldwide,
but the pathogenesis of HCV, especially the relationship
between HCV and HCC remains to be determined. Unlike
DNA virus HBV, which can integrate its virus DNA into a host
genome to cause HCC, HCV is an RNA virus. HCV patho-
genesis might involve its viral proteins. 
The oncogenic potential of HCV NS3 protein has been
well documented (8,9,14,15). The disturbance of cell
proliferation is closely associated with hepatocarcinogenesis.
So this work emphasized the effect of HCV NS3 protein on
cell proliferation. The proliferative advantage appears in the
immortally normal hepatocyte QSG7701 cells expressing
stably HCV NS3 protein, suggesting the potential role of HCV
NS3 protein in the promotion of cell growth. The results
provide an insight into the mechanisms of how the HCV NS3
protein mediates its oncogenic activity in infected cells and
are supported by previous findings (14,16,17). In addition, we
also show the HCV NS3-stimulated cell growth is ERK/AP-1
cascade dependent.
Cell proliferation and apoptosis are regulated accurately by
signaling cascades (18). Specifically the MAP kinase signaling
cascade plays a key role in hepatocarcinogenesis (19,20).
Mammals express mainly three distinctly regulated groups of
MAPK, extracellular signal-related kinases (ERK)-1/2, Jun
amino-terminal kinases (JNK) and p38 proteins. ERK1/2
cascade is mainly correlated to cell proliferation and survival.
Raf-1-mediated cell proliferation is dependent on the activation
of ERK, which progresses cells from G1 phase to S phase
(21). The suppression of ERK activation in fibroblasts by
antisense RNA or deficient mutants could inhibit the pro-
liferative response (22). Moreover, ERK plays a central role in
the regulation of the level of p27kip1 protein, which can bind
and inhibit cyclin E-Cdk2, block the G1/S transition (23). ERK
can also affect the progression of the cell cycle by phos-
phorylation and degradation of the p27kip1 protein (24). All
the information suggests that ERK is associated closely with
the progression of the cell cycle. We found HCV NS3 protein
induces activation of ERK signaling pathway together with
the promotion of cell growth. It suggests a potential role for
this pathway in the modulation of HCV NS3 protein-mediated
oncogenic activity in host cells. Therefore, the ability of the
ERK inhibitor to abrogate HCV NS3-induced cell growth
supports that ERK activation is an essential component in the
HCV NS3-stimulated cell growth.
As an important downstream effector of ERK, AP-1
regulates directly the expression of cyclin D1 to modulate the
progress of the cell cycle (25,26). ERK can stimulate the
induction of cyclin D1 by enhancing AP-1 activity indirectly,
resulting in cell proliferation (27). Silencing of AP-1 by
specific antisense oligonucleotides inhibited S phase entry
and cell proliferation (28-30). Our results demonstrated the
activation of ERK, AP-1 and its substrates cyclin D1 by HCV
NS3 protein and delineated the importance of the ERK/AP-1/
cyclin D1 cascade for modulation of HCV NS3 protein-
mediated cell growth. Thus, HCV NS3 protein could promote
cellular proliferation for maintenance of replication and
survival (31,32) by this cascade and contribute to hepato-
carcinogenesis. 
NF-κB is a signal transcription factor that has emerged as
an important modulator of altered gene programs and
malignant phenotype in the development of cancer. Major
carcinogens and oncogenic viruses induce NF-κB activation,
and a variety of subsequent oncogenic events contribute to a
progressive increase in constitutive NF-κB activation as an
important common pathway in most forms of cancer. NF-κB
target genes promote tumor cell proliferation, survival,
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Figure 4. Inhibition of HCV NS3 protein-induced AP-1 and NF-κB activation,
and cyclin D1 expression, and cell growth by ERKs inhibitor PD98059. One
of the three QSG7701/NS3 cell clones was taken randomly as experimental
cell clone, and the cells were pre-treated with PD98059 at 0, 30, 50 and 100
μM for 48 h. It is shown that the ERKs inhibitor, PD98059, specifically
inhibits activation of ERKs (A). The nuclear extracts were prepared and equal
amounts of nuclear proteins (6 μg) were analyzed for the activation of AP-1
(B) and NF-κB (C). Western blot analysis of the expression of cyclin D1 (D).
The same blots were re-probed with an anti-actin antibody to compare
loading and transfer. Measurement of cell growth in the presence or absence
of the ERK inhibitor PD98059 was taken by MMT assay (E).
Table III. FCM analysis of cell cycle.
–––––––––––––––––––––––––––––––––––––––––––––––––
Groups PD98059 (μM/ml) G1 (%) S (%)
–––––––––––––––––––––––––––––––––––––––––––––––––
1 0 μM/ml 64.6 22.5
2 30 μM/ml 66.8 20.7
3 50 μM/ml 68.7 19.9
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migration, inflammation, and angiogenesis (33). Guttridge et al
demonstrated NF-κB regulation of cyclin D1 occurs at the
transcriptional level and is mediated by direct binding of
NF-κB to multiple sites in the cyclin D1 promoter, which
induces cyclin D1 expression and promotes G1-to-S
progression (34). Moreover, the ERK substrate p90-RSK can
phosphorylate IκB and induce its degradation (35), and ERK
can down-regulate the expression of PAR-4, an inhibitor of
NF-κB activation (36,37), suggesting NF-κB activation may
be regulated by ERK. In this work, ERK inhibitor, PD98059,
inhibits activation of NF-κB in the HCV NS3 expressed cell.
This result indicates that, in addition to the ERK/AP-1/
cyclin D1 cascade, HCV NS3 protein-mediated cell growth
also involves the ERK/NF-κB/cyclin D1 cascade as well.
HCV NS3 protein mediated cell growth in liver and in
non-liver cell lines such as HepG2 and Hela, which have been
demonstrated to involve the activation of JNK/AP-1 signaling
pathway (16). However, different cell lines and methods were
used in these two studies, which might contribute to the
variation in outcomes (38,39). Although different signal
pathways may be involved, the potential role of HCV NS3
protein in the promotion of cell growth is consistent between
our study and others.
In summary, our data demonstrate HCV NS3 protein can
promote cell growth and contribute to hepatocarcinogenesis
by the activation of ERK/AP-1 and NF-κB/cyclin D1 cascades.
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